AVNS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Avanos Medical Inc (AVNS) is not a strong buy at this time for a beginner investor with a long-term strategy. While the stock has shown slight positive price movement and has bullish moving averages, the company's financial performance is weak with significant declines in net income, EPS, and gross margin. Additionally, there are no strong trading signals or recent positive catalysts to justify immediate investment. Holding off for better financial performance or stronger signals is recommended.
The stock's MACD is negative and expanding downward, indicating bearish momentum. RSI is neutral at 47.955, showing no clear overbought or oversold conditions. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), suggesting a positive trend. Key resistance is at 15.501, and support is at 13.797.
The company has nominated new independent directors to enhance board leadership and financial expertise. Analysts have raised price targets and provided positive ratings, indicating some confidence in the stock.
The company's Q4 financials show a significant net loss due to a goodwill impairment charge, with net income and EPS dropping sharply. Gross margin also declined year-over-year. No recent congress trading data or strong hedge fund/insider activity trends are available.
In Q4 2025, revenue increased slightly by 0.72% YoY to $180.9 million. However, net income dropped by 99.67% YoY to -$1.3 million, and EPS fell by 99.65% YoY to -$0.03. Gross margin decreased by 12.88% YoY to 47.54%. The company projects flat to slightly positive sales growth for 2026, between $700 million and $720 million.
Barclays raised its price target to $11 from $9 and maintains an Overweight rating. William Blair initiated coverage with an Outperform rating, citing the company's positioning as an attractive smid-cap healthcare services holding.
